Evidence map›Paper›PMID 42253058›Full record

ArticleEmerging microbes & infections2026

Identification of Prohibitin (PHB) as an Entry Factor of Highly Pathogenic Coronaviruses Using Metabolic Glycoengineering and Photo-Crosslinking Techniques.

Xingxing Zhu, Xiaoyang Wang, Yiming Wang, Xinchen Wang, Yuanhao Li, Liwen Hua, Honggao Duan, Rongding Yan, Tao Yuan, Jing Li and 4 more

Abstract read
In one paragraph

Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xingxing ZhuState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Xiaoyang WangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Yiming WangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Xinchen WangState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Yuanhao LiState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Liwen HuaState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Honggao DuanState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Rongding YanState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Tao YuanState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Jing LiState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Yeshuang YuanNational Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/ National Center of Gerontology, Beijing, People's Republic of China.
Bo ZhangState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Demin ZhouState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Sulong XiaoState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.ORCID 0000-0002-6852-9504

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronaviruses (CoVs) rely on host surface factors to mediate viral attachment and entry, yet conserved host cofactors shared across different CoVs remain poorly defined. Here, we established a host-factor capture platform based on metabolic glycoengineering and photo-crosslinking to identify host factors associated with CoV Spike proteins under near-physiological conditions. Using this approach, we identified prohibitin (PHB) as a candidate Spike-associated host factor shared by SARS-CoV, MERS-CoV, and SARS-CoV-2. Functional analyses showed that depletion of membrane-associated PHB decreased pseudovirus infection, whereas PHB reconstitution or overexpression enhanced susceptibility across multiple cell systems, including Huh7, BEAS-2B, Calu-3, and primary human airway epithelial cells (hAECs). In addition, antibody-mediated blockade of cell-surface PHB suppressed pseudovirus entry in both hAECs and human lung organoids. Immunohistochemical analyses further demonstrated PHB expression in normal human lung tissues. Mechanistically, recombinant PHB interacted with the Spike proteins of all three CoVs, and this association was supported by surface plasmon resonance and co-immunoprecipitation assays. Structural prediction combined with fragment-based alanine scanning identified residues 139-154 within the extracellular PHB domain as a critical region for efficient Spike association. Furthermore, PHB-associated pseudovirus entry was sensitive to lipid raft disruption, supporting a role for cholesterol-dependent membrane microdomains in this process. Together, these findings identify membrane-associated PHB as a conserved Spike-associated host factor linked to CoV entry.

Indexed as

BetacoronavirusRepressor ProteinsSpike Glycoprotein, CoronavirusVirus InternalizationAnimalsCell LineHumansMetabolic EngineeringProhibitinsSARS-CoV-2Severe acute respiratory syndrome-related coronavirusPHB protein, humanProhibitinsRepressor ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Ac4ManNAzcoronavirusphoto-crosslinking probeprohibitin (PHB)SARS-CoV-2

Identifiers

PMID42253058
PMCPMC13288833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.